Furukawa, H http://orcid.org/0000-0002-4022-0767
Oka, S
Tsuchiya, N http://orcid.org/0000-0002-6776-5580
Shimada, K
Hashimoto, A
Tohma, S
Kawasaki, A
Article History
Received: 26 July 2016
Revised: 26 September 2016
Accepted: 30 September 2016
First Online: 10 November 2016
Competing interests
: HF has the following conflicts, and the following funders are supported wholly or in part by the indicated pharmaceutical companies. The Japan Research Foundation for Clinical Pharmacology is run by Daiichi Sankyo, the Takeda Science Foundation is supported by an endowment from Takeda Pharmaceutical Company and the Nakatomi Foundation was established by Hisamitsu Pharmaceutical Co., Inc. The Daiwa Securities Health Foundation was established by Daiwa Securities Group Inc. and Mitsui Sumitomo Insurance Welfare Foundation was established by Mitsui Sumitomo Insurance Co., Ltd. HF received honoraria from Ajinomoto Co., Inc., Daiichi Sankyo Co., Ltd., Dainippon Sumitomo Pharma Co., Ltd., Pfizer Japan Inc., Takeda Pharmaceutical Company, Luminex Japan Corporation Ltd. and Ayumi Pharmaceutical Corporation. ST was supported by research grants from the pharmaceutical companies: Abbott Japan Co., Ltd., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Merck Sharp and Dohme Inc., Pfizer Japan Inc., Takeda Pharmaceutical Company Limited, and Teijin Pharma Limited. ST received honoraria from Asahi Kasei Pharma Corporation, Astellas Pharma Inc., AbbVie GK., Chugai Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation and Pfizer Japan Inc. NT was supported by SENSHIN Medical Research Foundation, which is supported by an endowment from Mitsubishi Tanabe Pharma Corporation, and received honoraria from Eisai Co., Ltd., Daiichi Sankyo Co., Ltd. and Asahi Kasei Corporation. The other authors declare no financial or commercial conflict of interest.